Skip to main content
. 2022 Nov 29;8(11):e37016. doi: 10.2196/37016

Table 3.

Prevalence of HIV, hepatitis B virus (HBV), and hepatitis D virus (HDV) triple infection in different subgroups.

Subgroup Studies, n Triple infection, n Prevalence, % (95% CI) I2, % P value
Global 14 877 7.4 (3.2-13.1) 99.0 <.001
World region

Europe 7 237 5.7 (3.2-8.2) 95.9 <.001

Africa 4 426 6.3 (0.7-11.8) 99.3 <.001

Asia 3 214 21.4 (7.1-35.8) 96.7 <.001
Country or area

France 2 31 6.3 (1.1-11.5) 81.4 .02

Italy 2 20 2.1 (0.5-4.7) 86.4 .007

Cameroon 1 390 20.2 (18.4-22.0) a <.001

Romania 1 21 10.2 (6.1-14.4)

Switzerland 1 117 14.3 (11.8-16.9)

China (Taiwan) 3 214 21.4 (7.1-35.8) 96.7 <.001

Guinea-Bissau 1 18 3.1 (1.7-4.5)

Nigeria 1 8 0.7 (0.2-1.2)
Sex

Male 8 212 3.8 (2.5-5.2) 95.3 <.001

Female 7 57 0.7 (0.2-1.2) 78.0 <.001
Age (years)

<30 1 21 5.6 (3.6-7.3)

≥30 8 269 5.1 (3.3-6.8) 96.2 <.001
Sample size

50-500 7 136 7.7 (4.2-11.1) 93.5 <.001

500-1000 4 282 11.8 (4.0-19.7) 98.9 <.001

>1000 3 459 7.2 (2.4-11.9) 99.5 <.001
Study population

HIV 5 116 1.7 (0.9-2.5) 84.8 <.001

HBV 4 560 13.4 (2.5-24.4) 99.4 <.001

HIV+HBV 5 201 11.9 (6.5-17.2) 92.5 <.001
Possible mode of HIV transmission

Injection drug use 6 274 7.4 (2.9-11.9) 97.9 <.001

Men who have sex with men 6 216 7.9 (4.3-11.4) 98.1 <.001

Heterosexual transmission 6 201 6.5 (3.4-9.6) 98 <.001

Other 6 248 10.3 (6.0-14.7) 98.4 <.001

aNot available.